Musburger Brooke G, Gonzalez Echeandia Maria, Suskind Elias L, Suskind David L, Zheng Hengqi Betty, Mark Dominique
Division of Pediatric Gastroenterology, Seattle Children's Hospital, Seattle, WA 98105, USA.
School of Life Sciences, Arizona State University, 427 E Tyler Mall, Tempe, AZ 85281, USA.
Pharmaceutics. 2025 Jun 7;17(6):753. doi: 10.3390/pharmaceutics17060753.
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the complex interaction of genetic predisposition and environmental triggers, both which contribute to esophageal inflammation. Current societal guidelines recommend the use of proton pump inhibitors, topical steroids, and dietary interventions such as elimination diets as first-line treatments, however, the recent approval of Dupliumab has provided an additional therapeutic avenue. There are a number of investigational biologic agents targeting other immune pathways which are making their way through the pipeline of pharmacologic options in treating this chronic disorder.
嗜酸性粒细胞性食管炎(EoE)是一种慢性免疫介导性疾病,其特征为食管功能障碍症状以及食管黏膜中嗜酸性粒细胞增多。它在儿童和成人中越来越普遍,其发病机制源于遗传易感性和环境触发因素的复杂相互作用,这两者都会导致食管炎症。目前的社会指南推荐使用质子泵抑制剂、局部类固醇以及饮食干预措施(如排除饮食)作为一线治疗方法,然而,最近度普利尤单抗的获批提供了另一种治疗途径。有许多针对其他免疫途径的研究性生物制剂正在进入治疗这种慢性疾病的药物选择流程。